Literature DB >> 11502935

A prospective natural history study of inclusion body myositis: implications for clinical trials.

M R Rose1, M P McDermott, C A Thornton, C Palenski, W B Martens, R C Griggs.   

Abstract

Eleven patients with untreated inclusion body myositis (IBM) were prospectively studied during a 6-month period that included muscle strength, lean body mass, and muscle mass measurements. There was an overall quantifiable mean decline in percent of predicted normal muscle strength of 4% from baseline in a 6-month period, but one third of patients showed no change or slight improvements in strength. Short-term treatment trials in IBM will require large numbers of patients to detect slowing, arrest, or even slight improvement in muscle strength.

Entities:  

Mesh:

Year:  2001        PMID: 11502935     DOI: 10.1212/wnl.57.3.548

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors:  Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

2.  Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.

Authors:  Linda Pax Lowes; Lindsay Alfano; Laurence Viollet; Xiomara Quintero Rosales; Zarife Sahenk; Brian K Kaspar; K Reed Clark; Kevin M Flanigan; Jerry R Mendell; Michael P McDermott
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

3.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

4.  Targeting protein homeostasis in sporadic inclusion body myositis.

Authors:  Mhoriam Ahmed; Pedro M Machado; Adrian Miller; Charlotte Spicer; Laura Herbelin; Jianghua He; Janelle Noel; Yunxia Wang; April L McVey; Mamatha Pasnoor; Philip Gallagher; Jeffrey Statland; Ching-Hua Lu; Bernadett Kalmar; Stefen Brady; Huma Sethi; George Samandouras; Matt Parton; Janice L Holton; Anne Weston; Lucy Collinson; J Paul Taylor; Giampietro Schiavo; Michael G Hanna; Richard J Barohn; Mazen M Dimachkie; Linda Greensmith
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

Review 5.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

6.  Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.

Authors:  Shahar Shelly; Michelle M Mielke; Jay Mandrekar; Margherita Milone; Floranne C Ernste; Elie Naddaf; Teerin Liewluck
Journal:  Neurology       Date:  2021-04-20       Impact factor: 11.800

7.  Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.

Authors:  Mark A Price; Victoria Barghout; Olivier Benveniste; Lisa Christopher-Stine; Alastair Corbett; Marianne de Visser; David Hilton-Jones; John T Kissel; Thomas E Lloyd; Ingrid E Lundberg; Francis Mastaglia; Tahseen Mozaffar; Merrilee Needham; Jens Schmidt; Kumaraswamy Sivakumar; Carla DeMuro; Brian S Tseng
Journal:  J Neuromuscul Dis       Date:  2016-03-03

8.  Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Authors:  J B Lilleker; A Rietveld; S R Pye; K Mariampillai; O Benveniste; M T J Peeters; J A L Miller; M G Hanna; P M Machado; M J Parton; K R Gheorghe; U A Badrising; I E Lundberg; S Sacconi; M K Herbert; N J McHugh; B R F Lecky; C Brierley; D Hilton-Jones; J A Lamb; M E Roberts; R G Cooper; C G J Saris; G J M Pruijn; H Chinoy; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2017-01-25       Impact factor: 19.103

Review 9.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423

Review 10.  Update in inclusion body myositis.

Authors:  Pedro Machado; Stefen Brady; Michael G Hanna
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.